Proceedings from a CME webinar held in partnership with the American Society of Clinical Oncology. Featuring perspectives from Drs Jeff Sharman and Julie M Vose on the following topics:

• Introduction (00:00)
• Chronic Lymphocytic Leukemia (1:49)
• Follicular Lymphoma (37:48)

CME information and select publications

Featuring an interview with Dr Kim Reiss Binder on recent advances in the use of PARP inhibitors in pancreatic cancer, including the following topics:

• PARP inhibitors in pancreatic cancer — Kim Reiss Binder, MD (00:00)
• Case: A man in his late 50s with metastatic pancreatic adenocarcinoma and a germline BRCA2 mutation attains a good response to maintenance olaparib after treatment with platinum-based chemotherapy (32:40)
• Case: A man in his early 50s with metastatic pancreatic adenocarcinoma and a PALB2 mutation receives maintenance rucaparib on a clinical trial (37:54)
• Case: A woman in her late 50s with metastatic pancreatic adenocarcinoma experiences a complete response to the combination of niraparib and ipilimumab on the Parpvax trial after receiving chemotherapy (41:59)

CME information and select publications

Featuring a roundtable discussion with Drs Andrew J Armstrong, Celestia S Higano, David F Penson and Neal D Shore on the following topics:

• Optimizing the Choice of Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
• • Selection of chemotherapy or secondary hormonal therapy (enzalutamide, abiraterone, apalutamide) to administer with androgen deprivation therapy (ADT) (0:00)
  • Management of HSPC in patients with de novo asymptomatic metastases (9:04)
  • Use of secondary hormonal therapy or chemotherapy in addition to ADT for patients with mHSPC in community-based practices (15:53)
  • Effect of patient age and comorbidities on choice of therapy for mHSPC (21:15)
  • Clinical outcomes with the addition of chemotherapy or secondary hormonal therapy to ADT for patients with mHSPC (29:42)
  • Tolerability and side-effect profiles of abiraterone/prednisone and enzalutamide (33:32)
  • Paradigm shift in the management of mHSPC — Neal D Shore, MD (37:36)
  • Case: A man in his late 60s with mHSPC achieves a good clinical response to ADT and apalutamide (53:51)
  • Case: A man in his early 50s with HSPC and extensive bone metastases (55:11)
  • Overall survival outcomes with the addition of secondary hormonal therapy or chemotherapy to ADT; management of the primary tumor in patients with mHSPC (57:35)
  • Practical factors influencing the selection of therapy for patients with mHSPC — David F Penson, MD, MPH, MMHC (1:02:39)
  • Case: A man in his late 50s with mHSPC and a BRCA2 mutation receives abiraterone and prednisone after treatment with docetaxel and ADT (1:21:49)
  • Balancing the risks and benefits of secondary hormonal therapy (1:25:47)
• Selection and Sequencing of Therapies for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• • Choice of therapy based on symptoms and site of metastases for patients with mCRPC (1:27:28)
  • Management of mCRPC after disease progression on secondary hormonal therapy; testing for AR-V7 to predict resistance (1:32:29)
  • Clinical experience with the PARP inhibitors olaparib and rucaparib; activity of cabazitaxel in patients with mCRPC (1:36:54)
  • Recent FDA approval of rucaparib and olaparib for mCRPC; implications for genetic testing and routine practice (1:39:40)
  • Sequencing of therapies for men with mCRPC — Celestia S Higano, MD (1:46:36)
  • Promising agents and strategies for men with metastatic prostate cancer — Andrew J Armstrong, MD, ScM (2:04:40)

CME information and select publications

Featuring an interview with Dr Courtney D DiNardo on recent data on the management of acute myeloid leukemia not eligible for intensive induction therapy, including the following topics:

• Management of Acute Myeloid Leukemia in Patients Not Eligible for Intensive Induction Therapy — Courtney D DiNardo, MD, MSCE (00:00)
• Case: A woman in her mid-70s with AML and diploid cytogenetics with mutations in NPM1, IDH1 and FLT3-TKD who receives venetoclax with a hypomethylating agent (21:20)
• Case: A man in his late 60s with AML with del(5q), del(7q) and mutations in RUNX1 and SRSF2 (28:57)
• Case: A woman in her late 60s with relapsed/refractory AML with intermediate-risk cytogenetics (35:22)

CME information and select publications

Proceedings from the third in a 3-part webinar series. Featuring perspectives from Drs Marcia S Brose, Andrew McKenzie and Milan Radovich, including on the following topics:

• Part 1: Molecular Tumor Board
• • Introduction (00:00)
  • Case: A woman in her late 70s with ER-positive, HER2-negative metastatic breast cancer (ESR, CHEK2 and RET mutations) — Sulfi Ibrahim, MD (6:09)
  • Case: A woman in her mid-40s with metastatic thymoma (MTOR gain-of-function mutation) — Milan Radovich, PhD (13:29)
  • Case: A patient with leiomyosarcoma (BRCA germline mutation) — Andrew McKenzie, PhD (15:05)
  • Case: A patient with bone-only disease — Dr Ibrahim (16:44)
• Part 2: New Molecular Targets in Thyroid Cancer
• • Case: A woman in her late 30s with RAI-refractory papillary thyroid cancer — Marcia S Brose, MD, PhD (21:25)
  • Case: A man in his late 60s with papillary thyroid cancer — Dr Brose (29:25)
  • Case: A woman in her late teens with locally advanced medullary thyroid cancer — Dr Brose (36:04)
  • Case: A frail woman in her late 70s with metastatic papillary thyroid cancer (CAD) — Dr Ibrahim (39:46)
  • Case: A man in his late 50s with metastatic thyroid cancer (RET M918T gain-of-function mutation) — Dr Radovich (43:40)
  • Case: A man in his early 70s with metastatic medullary thyroid cancer (RET mutation) — Dr McKenzie (46:27)
• Part 3: Targeting the FGFR Signaling Pathway in Cholangiocarcinoma
• • Case: A woman in her late 50s with metastatic cholangiocarcinoma (FGFR2-BICC1 fusion) — Dr Radovich (48:28)
• Part 4: New Options in the Management of GIST Harboring PDGFR Mutations
• • Case: A patient with GIST (PDGFRA) — Dr McKenzie (52:57)
  • Case: A woman in her early 60s with metastatic GIST (gain-of-function PDGFRA D842Y mutation) — Dr Radovich (54:23)
• Part 5: Molecular Tumor Board (Continued)
• • Case: A man in his late 70s with metastatic pancreatic cancer (EGFR exon 19 deletion) — Justin Peter Favaro, MD, PhD (55:30)

CME information and select publications